CA2750074A1 - Use of cardiotrophin-1 for the treatment of metabolic diseases - Google Patents

Use of cardiotrophin-1 for the treatment of metabolic diseases Download PDF

Info

Publication number
CA2750074A1
CA2750074A1 CA2750074A CA2750074A CA2750074A1 CA 2750074 A1 CA2750074 A1 CA 2750074A1 CA 2750074 A CA2750074 A CA 2750074A CA 2750074 A CA2750074 A CA 2750074A CA 2750074 A1 CA2750074 A1 CA 2750074A1
Authority
CA
Canada
Prior art keywords
compound
cardiotrophin
activity
treatment
induces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2750074A
Other languages
English (en)
French (fr)
Inventor
Jesus Maria Prieto Valtuena
Matilde Bustos De Abajo
Maria Jesus Moreno Aliaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Universidad de Navarra
Original Assignee
Proyecto de Biomedicina CIMA SL
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL, Instituto Cientifico y Tecnologico de Navarra SA filed Critical Proyecto de Biomedicina CIMA SL
Publication of CA2750074A1 publication Critical patent/CA2750074A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2750074A 2009-02-12 2010-02-10 Use of cardiotrophin-1 for the treatment of metabolic diseases Abandoned CA2750074A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900396 2009-02-12
ESP200900396 2009-02-12
PCT/ES2010/070072 WO2010092218A2 (es) 2009-02-12 2010-02-10 Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas

Publications (1)

Publication Number Publication Date
CA2750074A1 true CA2750074A1 (en) 2010-08-19

Family

ID=42562119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2750074A Abandoned CA2750074A1 (en) 2009-02-12 2010-02-10 Use of cardiotrophin-1 for the treatment of metabolic diseases

Country Status (11)

Country Link
US (1) US20110293562A1 (enExample)
EP (1) EP2397152B1 (enExample)
JP (1) JP2012517459A (enExample)
CN (1) CN102316892B (enExample)
AU (1) AU2010212794A1 (enExample)
BR (1) BRPI1008415A2 (enExample)
CA (1) CA2750074A1 (enExample)
ES (1) ES2493618T3 (enExample)
MX (1) MX2011008562A (enExample)
RU (1) RU2011137413A (enExample)
WO (1) WO2010092218A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419916B2 (en) 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
WO2015127474A1 (en) * 2014-02-24 2015-08-27 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
CA2318152A1 (en) 1998-01-29 1999-08-05 Poly-Med Inc. Absorbable microparticles
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
AU2003257938A1 (en) * 2002-07-29 2004-02-16 Es Cell International Pte Ltd. Multi-step method for differentiation of insulin positive, glucose
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
US20080207493A1 (en) * 2005-03-17 2008-08-28 Novo Nordisk A/S Compounds for Use in the Treatment of Obesity
BRPI0707869A2 (pt) 2006-02-15 2011-05-10 Sanofi Aventis ariltienopirimidinonas substituÍdas com azaciclil, processo para a sua preparaÇço e seus usos como medicamentos

Also Published As

Publication number Publication date
BRPI1008415A2 (pt) 2018-02-27
WO2010092218A2 (es) 2010-08-19
AU2010212794A1 (en) 2011-08-11
MX2011008562A (es) 2011-09-09
WO2010092218A3 (es) 2010-11-18
ES2493618T3 (es) 2014-09-12
EP2397152B1 (en) 2014-05-28
RU2011137413A (ru) 2013-03-20
CN102316892A (zh) 2012-01-11
US20110293562A1 (en) 2011-12-01
CN102316892B (zh) 2014-06-04
JP2012517459A (ja) 2012-08-02
EP2397152A2 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
Wesson et al. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension
Mahgoub et al. An update on the molecular and cellular basis of pharmacotherapy in type 2 diabetes mellitus
KR102035879B1 (ko) 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
CN104981240B (zh) 通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途
Tahrani et al. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
US20150057306A1 (en) Compositions comprising scopolamine and ketamine in the treatment of depression
JP2011241213A5 (enExample)
JP2010518164A5 (enExample)
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
AU2014207748B2 (en) Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
US20220226283A1 (en) Combination product containing limonoid compound and dpp-4 inhibitor
JP2018511639A (ja) 自閉症を治療するための組成物及び方法
Yoon et al. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials
CN110339176A (zh) 包含吉格列汀和二甲双胍的组合药物及其制备方法
Gallwitz Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
Lukitasari et al. 28 Green tea extract administration had a beneficial effect on ppar alpha and ppar gamma gene expression in metabolic syndrome rat model
RU2011137413A (ru) Применение кардиотрофина-1 для лечения метаболических заболеваний
JP2012517459A5 (enExample)
AU2024229800A1 (en) Methods of treating essential tremor
CN104906114A (zh) 一种二甲双胍格列喹酮复方缓释胶囊及制备方法
Hoimark et al. Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
Nugroho et al. 29 DOSE-DEPENDENT EFFECTS OF GREEN TEA EXTRACT ON ADIPONECTIN LEVEL AND ADIPONECTIN RECEPTOR GENE EXPRESSION IN METABOLIC SYNDROME RAT MODELS
KR20180053032A (ko) 신규한 피페린 유도체 및 이를 포함하는 약학적 조성물
Adnan Type 2 diabetic patients fasting on Ramadan in Israel
KR20220119065A (ko) 불면증 치료를 위한 렘보렉산트의 용도

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160210